ArticleBlood cancer journal2024
CD56 expression predicts response to Daratumumab-based regimens.
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma.Journal of clinical medicine · 2026Article
- Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era.Haematologica · 2025Article
- CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.Oncoimmunology · 2025Article
- CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.Blood cancer journal · 2025Article
- CD56 on immune and tumor cells: what is known and beyond?Clinical and experimental immunology · 2025Review
- Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry: a call for harmonized gating strategies.Frontiers in immunology · 2025Review
- CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma.Leukemia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.